5-methyl-2-trimethylstannylbenzo[b]thiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-methyl-2-trimethylstannylbenzo[b]thiophene
• 英文别名: trimethyl-(5-methyl-1-benzothiophen-2-yl)stannane
• 化学式: C₁₂H₁₆SSn
• 分子量: 311.035
• InChiKey: ZRDKLFMDYUVKRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.75
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-methyl-2-trimethylstannylbenzo[b]thiophene 、 2-碘氰基苯 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 生成 2-(2'-cyanophenyl)-5-methylbenzo[b]thiophene
  参考文献：
  名称：

  N-acyl-n-quinolinyl or isoquinounyl alkylamino acids compositions and

  摘要：

  该发明涉及公式为N-acyl-N-杂环烷基氨基酸的化合物。这些化合物及其药用盐可用作降压药、治疗青光眼的药物，或用于增加视网膜眼液的流动。

  公开号：

  US05506240A1
• 作为产物：
  描述：

  5-甲基苯并噻吩 、 三甲基氯化锡 在 正丁基锂 、 ammonium chloride 作用下， 以 正己烷 为溶剂， 生成 5-methyl-2-trimethylstannylbenzo[b]thiophene
  参考文献：
  名称：

  N-acyl-n-quinolinyl or isoquinounyl alkylamino acids compositions and

  摘要：

  该发明涉及公式为N-acyl-N-杂环烷基氨基酸的化合物。这些化合物及其药用盐可用作降压药、治疗青光眼的药物，或用于增加视网膜眼液的流动。

  公开号：

  US05506240A1

文献信息

• N-acyl-N-heterocyclylalkylamino acid compounds and method of use thereof
  申请人：Ciba-Geigy Corporation

  公开号：US05620998A1

  公开（公告）日：1997-04-15

  The invention relates to N-acyl-N-heterocyclylalkylamino acids of the formula ##STR1## wherein Y.sub.1 is O, S or N(R) and R is hydrogen or C.sub.1 -C.sub.7 alkyl; X.sub.1 is --CO-- or --S(O).sub.m -- and the index m is 0, 1 or 2; one of the variables X.sub.2 and X.sub.4 is C.sub.1 -C.sub.4 alkylene and the other of the variables X.sub.2 and X.sub.4 is a bond; or each of the variables X.sub.2 and X.sub.4 is a bond; X.sub.3 is C.sub.3 -C.sub.7 cycloalkylidene or the structural element --C(X.sub.a)(X.sub.b)-- and X.sub.a is hydrogen or C.sub.1 -C.sub.7 alkyl and X.sub.b is C.sub.1 -C.sub.7 alkyl; and the rings A, B and C, with the exception of the substituents indicated in the formula, and also aromatic substituents are, independently of one another, unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of halogen, C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.7 alkoxy, C.sub.2 -C.sub.7 alkenyloxy, phenoxy, benzyloxy, trifluoromethyl and S(O).sub.m --R, wherein m is 0, 1 or 2 and R is hydrogen or C.sub.1 -C.sub.7 alkyl; or a salt thereof.

  本发明涉及式（I）的N-酰基-N-杂环基烷基氨基酸，其中Y1为O，S或N（R），R为氢或C1-C7烷基；X1为--CO--或--S（O）m--，指数m为0，1或2；变量X2和X4中的一个为C1-C4烷基，另一个为键；或变量X2和X4均为键；X3为C3-C7环烷基亚甲基或结构元素--C（Xa）（Xb）--，其中Xa为氢或C1-C7烷基，Xb为C1-C7烷基；除公式中指示的取代基外，环A、B和C以及芳香族取代基独立地未取代或被取代为单个或多个来自卤素、C1-C7烷基、C1-C7烷氧基、C2-C7烯基氧基、苯氧基、苄氧基、三氟甲基和S（O）m--R的取代基中选择的取代基；或其盐。
• N-acyl-N-heterocyclylalkyamino acids compositions and method of use
  申请人：Ciba-Geigy Corporation

  公开号：US05955487A1

  公开（公告）日：1999-09-21

  The invention relates to N-acyl-N-heterocyclylalkylamino acids of the formula ##STR1## R.sub.1 is C.sub.1 -C.sub.7 alkyl that is unsubstituted or substituted by halogen or by hydroxy, or is C.sub.2 -C.sub.7 -alkenyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkoxy, C.sub.1 -C.sub.7 alkoxy or C.sub.3 -C.sub.7 cycloalkyl-C.sub.1 -C.sub.7 alkoxy; R.sub.2 is 1H-tetrazol-5-yl, carboxy, C.sub.1 -C.sub.7 alkoxycarbonyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or halo-C.sub.1 -C.sub.7 alkanesulfonylamino; R.sub.3 is 1H-tetrazol-5-yl, hydroxymethyl, C.sub.1 -C.sub.7 alkoxymethyl, formyl, carboxy, C.sub.1 -C.sub.7 alkoxycarbonyl, C.sub.1 -C.sub.7 alkoxy-C.sub.1 -C.sub.7 alkoxycarbonyl, phenyl-C.sub.1 -C.sub.4 alkoxycarbonyl or carbamoyl, the amino group of which is unsubstituted or mono-substituted by C.sub.1 -C.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl or by phenyl-C.sub.1 -C.sub.7 alkyl or di-substituted by C.sub.1 -C.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl or by phenyl-C.sub.1 -C.sub.7 alkyl independently of one another, or is di-substituted by C.sub.2 -C.sub.7 alkylene or by C.sub.2 -C.sub.4 alkyleneoxy-C.sub.2 -C.sub.4 alkylene; Alk is methylene, ethylene or ethylidene; and their salts; preparation processes, pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and use.

  本发明涉及式为##STR1##的N-酰基-N-杂环基烷基氨基酸；其中，R.sub.1是未取代或被卤素或羟基取代的C.sub.1-C.sub.7烷基，或是C.sub.2-C.sub.7烯基，C.sub.3-C.sub.7环烷基，C.sub.3-C.sub.7环烷氧基，C.sub.1-C.sub.7烷氧基或C.sub.3-C.sub.7环烷基-C.sub.1-C.sub.7烷氧基；R.sub.2是1H-四唑-5-基，羧基，C.sub.1-C.sub.7烷氧羰基，SO.sub.3H，PO.sub.2H.sub.2，PO.sub.3H.sub.2或卤代的C.sub.1-C.sub.7烷基磺酰氨基；R.sub.3是1H-四唑-5-基，羟甲基，C.sub.1-C.sub.7烷氧甲基，甲酰基，羧基，C.sub.1-C.sub.7烷氧羰基，C.sub.1-C.sub.7烷氧基-C.sub.1-C.sub.7烷氧羰基，苯基-C.sub.1-C.sub.4烷氧羰基或氨基，其氨基未被取代或被C.sub.1-C.sub.7烷基，C.sub.3-C.sub.7烯基或苯基-C.sub.1-C.sub.7烷基单取代或C.sub.1-C.sub.7烷基，C.sub.3-C.sub.7烯基或苯基-C.sub.1-C.sub.7烷基双取代，且彼此独立，或被C.sub.2-C.sub.7烷基或C.sub.2-C.sub.4烷氧基-C.sub.2-C.sub.4烷基双取代；Alk是亚甲基，乙烯基或乙基亚甲基；以及它们的盐；制备方法，包括式I化合物或其药学上可接受的盐的制药组合物，以及用途。